
    
      This is a multicenter, prospective, open-labeled, 2-arm, non-comparative randomized (2:1)
      phase II trial. Patients will be randomized between arm A (gemcitabine + berzosertib) and arm
      B (gemcitabine) with two patients randomized in arm A for one patient randomized in arm B.
    
  